KR102519540B1 - 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현 - Google Patents

재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현 Download PDF

Info

Publication number
KR102519540B1
KR102519540B1 KR1020227019897A KR20227019897A KR102519540B1 KR 102519540 B1 KR102519540 B1 KR 102519540B1 KR 1020227019897 A KR1020227019897 A KR 1020227019897A KR 20227019897 A KR20227019897 A KR 20227019897A KR 102519540 B1 KR102519540 B1 KR 102519540B1
Authority
KR
South Korea
Prior art keywords
cell
cells
culture
receptor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227019897A
Other languages
English (en)
Korean (ko)
Other versions
KR20220086703A (ko
Inventor
시바니 굽타
소혜 강
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102519540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20220086703A publication Critical patent/KR20220086703A/ko
Application granted granted Critical
Publication of KR102519540B1 publication Critical patent/KR102519540B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020227019897A 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현 Active KR102519540B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
US61/933,137 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
KR1020217028516A KR102410393B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028516A Division KR102410393B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현

Publications (2)

Publication Number Publication Date
KR20220086703A KR20220086703A (ko) 2022-06-23
KR102519540B1 true KR102519540B1 (ko) 2023-04-10

Family

ID=53757626

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227019897A Active KR102519540B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
KR1020217028516A Active KR102410393B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
KR1020167021676A Active KR102301034B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217028516A Active KR102410393B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
KR1020167021676A Active KR102301034B1 (ko) 2014-01-29 2014-12-11 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현

Country Status (14)

Country Link
US (3) US10227627B2 (https=)
EP (1) EP3099806A1 (https=)
JP (4) JP6474420B2 (https=)
KR (3) KR102519540B1 (https=)
CN (2) CN106170554B (https=)
AU (3) AU2014380174C1 (https=)
BR (1) BR112016017606A2 (https=)
CA (1) CA2938079C (https=)
CL (1) CL2016001900A1 (https=)
EA (2) EA037565B1 (https=)
IL (3) IL282517B (https=)
MX (2) MX377780B (https=)
SG (1) SG10201912081RA (https=)
WO (1) WO2015116315A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CA3056011A1 (en) * 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
EP3980524A4 (en) * 2019-06-10 2023-01-11 Cho Plus Inc. Cell lines for high level production of protein-based pharmaceuticals
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
EP4334356A1 (en) * 2021-05-03 2024-03-13 Boehringer Ingelheim International Gmbh Method for producing spesolimab
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2011134643A1 (en) 2010-04-27 2011-11-03 Lonza Ltd. Improved glycosylation of proteins in host cells
JP2012506710A (ja) 2008-10-31 2012-03-22 ロンザ リミテッド 宿主細胞中での糖鎖付加タンパク質の産生のための新規ツール

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2557046A1 (en) * 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
AU2010240569A1 (en) * 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2011127322A1 (en) * 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US9376484B2 (en) 2012-01-11 2016-06-28 Sigma-Aldrich Co. Llc Production of recombinant proteins with simple glycoforms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
JP2012506710A (ja) 2008-10-31 2012-03-22 ロンザ リミテッド 宿主細胞中での糖鎖付加タンパク質の産生のための新規ツール
WO2011134643A1 (en) 2010-04-27 2011-11-03 Lonza Ltd. Improved glycosylation of proteins in host cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Exp Hematol.,35(8):1279-1292(2007.8.)
Glycobiology.,21(7):949-959(2011.3.18.)

Also Published As

Publication number Publication date
CN106170554A (zh) 2016-11-30
JP7034236B2 (ja) 2022-03-11
CA2938079C (en) 2022-10-11
CN106170554B (zh) 2021-08-17
AU2014380174A1 (en) 2016-08-11
CN113774084A (zh) 2021-12-10
KR102410393B1 (ko) 2022-06-16
AU2018264100A1 (en) 2018-12-06
JP6474420B2 (ja) 2019-02-27
AU2018264100B2 (en) 2020-07-23
US20200277642A1 (en) 2020-09-03
AU2014380174C1 (en) 2025-06-05
IL246914B (en) 2019-12-31
AU2020239681C1 (en) 2025-06-05
IL270861B (en) 2021-05-31
CL2016001900A1 (es) 2017-05-12
IL282517A (en) 2021-06-30
US10655156B2 (en) 2020-05-19
JP6797950B2 (ja) 2020-12-09
KR102301034B1 (ko) 2021-09-13
EA037565B1 (ru) 2021-04-14
US10227627B2 (en) 2019-03-12
KR20210114549A (ko) 2021-09-23
JP7788307B2 (ja) 2025-12-18
AU2020239681A1 (en) 2020-10-15
AU2018264100C1 (en) 2025-06-05
IL282517B (en) 2022-07-01
US10907186B2 (en) 2021-02-02
JP2021040638A (ja) 2021-03-18
MX2016009911A (es) 2016-10-28
SG10201912081RA (en) 2020-02-27
EA201691532A1 (ru) 2017-01-30
JP2022068365A (ja) 2022-05-09
EP3099806A1 (en) 2016-12-07
US20190153496A1 (en) 2019-05-23
JP2017505620A (ja) 2017-02-23
AU2020239681B2 (en) 2022-06-23
BR112016017606A2 (pt) 2017-10-10
IL246914A0 (en) 2016-09-29
CA2938079A1 (en) 2015-08-06
WO2015116315A1 (en) 2015-08-06
KR20160111943A (ko) 2016-09-27
EA202190244A2 (ru) 2021-05-31
MX2020012356A (es) 2021-01-29
KR20220086703A (ko) 2022-06-23
CN113774084B (zh) 2024-04-16
JP2019088305A (ja) 2019-06-13
EA202190244A3 (ru) 2021-08-31
US20190010532A1 (en) 2019-01-10
MX377780B (es) 2025-03-11
IL270861A (en) 2020-01-30
AU2014380174B2 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
AU2018201844C1 (en) Use Of Monensin To Regulate Glycosylation Of Recombinant Proteins
US10106829B2 (en) Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK40126725A (en) Use of monensin to regulate glycosylation of recombinant proteins
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
HK1231928A1 (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4